Citadel Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Citadel Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.9K	Buy	+21,306	New	+$55.2K	﹤0.01%	13211
2024 Q1	–	Sell	-631	Closed	-$106K	–	15255
2023 Q4	$106K	Buy	631 +299	+90%	+$66.7K	﹤0.01%	10865
2023 Q3	$42.4K	Sell	332 -234	-41%	-$44.2K	﹤0.01%	11941
2023 Q2	$141K	Buy	+566	New	+$167K	﹤0.01%	10424
2021 Q3	–	Sell	-20	Closed	-$83K	–	14432
2021 Q2	$83K	Sell	20 -6	-23%	-$23.2K	﹤0.01%	13055
2021 Q1	$143K	Buy	+26	New	+$121K	﹤0.01%	12104

Other funds holding PCSA

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors's PCSA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Processa Pharmaceuticals (PCSA) in Q2 2026: 21,306 shares worth $40.9K. The stake represents ﹤0.01% of the portfolio and ranks #13211 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PCSA as recently as Q4 2023.

Citadel Advisors first reported a position in PCSA in Q1 2021 and has held it in 6 quarters since. The position peaked at $143K in Q1 2021. 12 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

Citadel Advisors held 21,306 shares of Processa Pharmaceuticals worth $40.9K as of Q2 2026.
Processa Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
Processa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13211 holding.
Citadel Advisors first reported a position in Processa Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
Citadel Advisors's Processa Pharmaceuticals position peaked at $143K in Q1 2021.
12 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.